Viva Biotech

Viva Biotech, founded in 2008, operates a world-leading, structure-based, integrated drug discovery platform. It provides specialized structure-based drug discovery services to global biotechnology and pharmaceutical customers for preclinical stage innovative drug development. The company leverages advanced structural biology techniques to identify new therapeutic targets and optimize drug candidates, significantly enhancing the efficiency and success rates of its partners' R&D pipelines. Viva Biotech's core expertise lies in accelerating the journey of novel therapies from initial concept through to clinical trials, offering a sophisticated suite of services.

The company's integrated, one-stop platform delivers a comprehensive range of professional technical services, including protein structure determination and custom drug design. Employing 1,000 - 5,000 professionals, Viva Biotech houses a substantial team of scientists and technical experts committed to scientific excellence and client outcomes. This dedicated workforce enables the company to manage complex discovery projects effectively. To learn more about the personnel driving these advancements, users can explore Meet Viva Biotech's team. Their operational model supports global service delivery, ensuring clients worldwide benefit from specialized capabilities in drug discovery and preclinical research.

Viva Biotech has secured significant private equity funding, notably in 2023 from investors like Temasek and HighLight Capital, underscoring its market confidence. The company reported a revenue of $332.5M, demonstrating robust financial performance and high demand for its specialized services. This financial stability fuels continued investment in its technology platform and service expansion. For detailed fiscal information, users can Explore financial highlights. Viva Biotech's strategic emphasis on innovation-driven drug discovery and its commitment to deliveringView more...